224 related articles for article (PubMed ID: 17063120)
1. Anti-OX40 (CD134) administration to nonhuman primates: immunostimulatory effects and toxicokinetic study.
Weinberg AD; Thalhofer C; Morris N; Walker JM; Seiss D; Wong S; Axthelm MK; Picker LJ; Urba WJ
J Immunother; 2006; 29(6):575-85. PubMed ID: 17063120
[TBL] [Abstract][Full Text] [Related]
2. Requirements for the functional expression of OX40 ligand on human activated CD4+ and CD8+ T cells.
Kondo K; Okuma K; Tanaka R; Zhang LF; Kodama A; Takahashi Y; Yamamoto N; Ansari AA; Tanaka Y
Hum Immunol; 2007 Jul; 68(7):563-71. PubMed ID: 17584577
[TBL] [Abstract][Full Text] [Related]
3. Anti-OX40 stimulation in vivo enhances CD8+ memory T cell survival and significantly increases recall responses.
Ruby CE; Redmond WL; Haley D; Weinberg AD
Eur J Immunol; 2007 Jan; 37(1):157-66. PubMed ID: 17183611
[TBL] [Abstract][Full Text] [Related]
4. Immunotoxicity profile of natalizumab.
Wehner NG; Gasper C; Shopp G; Nelson J; Draper K; Parker S; Clarke J
J Immunotoxicol; 2009 Jun; 6(2):115-29. PubMed ID: 19589098
[TBL] [Abstract][Full Text] [Related]
5. OX40 (CD134) expression in sentinel lymph nodes correlates with prognostic features of primary melanomas.
Sarff M; Edwards D; Dhungel B; Wegmann KW; Corless C; Weinberg AD; Vetto JT
Am J Surg; 2008 May; 195(5):621-5; discussion 625. PubMed ID: 18374895
[TBL] [Abstract][Full Text] [Related]
6. [Novel vaccines against M. tuberculosis].
Okada M
Kekkaku; 2006 Dec; 81(12):745-51. PubMed ID: 17240920
[TBL] [Abstract][Full Text] [Related]
7. Fetal calf serum-primed dendritic cells induce a strong anti-fetal calf serum immune response and diabetes protection in the non-obese diabetic mouse.
Kadri N; Potiron N; Ouary M; Jegou D; Gouin E; Bach JM; Lieubeau B
Immunol Lett; 2007 Feb; 108(2):129-36. PubMed ID: 17196260
[TBL] [Abstract][Full Text] [Related]
8. Humoral and cellular immune responses of nonhuman primates to long-term repeated lung exposure to Ad2/CFTR-2.
Kaplan JM; St George JA; Pennington SE; Keyes LD; Johnson RP; Wadsworth SC; Smith AE
Gene Ther; 1996 Feb; 3(2):117-27. PubMed ID: 8867859
[TBL] [Abstract][Full Text] [Related]
9. Allogeneic GM-CSF-secreting tumor cell immunotherapies generate potent anti-tumor responses comparable to autologous tumor cell immunotherapies.
Li B; Simmons A; Du T; Lin C; Moskalenko M; Gonzalez-Edick M; VanRoey M; Jooss K
Clin Immunol; 2009 Nov; 133(2):184-97. PubMed ID: 19664962
[TBL] [Abstract][Full Text] [Related]
10. OX40 Stimulation Enhances Protective Immune Responses Induced After Vaccination With Attenuated Malaria Parasites.
Othman AS; Franke-Fayard BM; Imai T; van der Gracht ETI; Redeker A; Salman AM; Marin-Mogollon C; Ramesar J; Chevalley-Maurel S; Janse CJ; Arens R; Khan SM
Front Cell Infect Microbiol; 2018; 8():247. PubMed ID: 30073152
[TBL] [Abstract][Full Text] [Related]
11. Cooperation between CD4 and CD8 T cells for anti-tumor activity is enhanced by OX40 signals.
Song A; Song J; Tang X; Croft M
Eur J Immunol; 2007 May; 37(5):1224-32. PubMed ID: 17429847
[TBL] [Abstract][Full Text] [Related]
12. Chronic administration of belatacept, a T-cell costimulatory signal blocker, in cynomolgus monkeys.
Haggerty HG; Proctor SJ
Toxicol Sci; 2012 May; 127(1):159-68. PubMed ID: 22331490
[TBL] [Abstract][Full Text] [Related]
13. Growth and differentiation advantages of CD4+ OX40+ T cells from allogeneic hematopoietic stem cell transplantation recipients.
Shindo T; Ishikawa T; Fukunaga A; Hori T; Uchiyama T
Biol Blood Marrow Transplant; 2008 Mar; 14(3):268-81. PubMed ID: 18275893
[TBL] [Abstract][Full Text] [Related]
14. Adenovirus 5- and 35-based immunotherapy enhances the strength but not breadth or quality of immunity during chronic SIV infection.
Soloff AC; Liu X; Gao W; Day RD; Gambotto A; Barratt-Boyes SM
Eur J Immunol; 2009 Sep; 39(9):2437-49. PubMed ID: 19670380
[TBL] [Abstract][Full Text] [Related]
15. A nonhuman primate model for the selective elimination of CD8+ lymphocytes using a mouse-human chimeric monoclonal antibody.
Schmitz JE; Simon MA; Kuroda MJ; Lifton MA; Ollert MW; Vogel CW; Racz P; Tenner-Racz K; Scallon BJ; Dalesandro M; Ghrayeb J; Rieber EP; Sasseville VG; Reimann KA
Am J Pathol; 1999 Jun; 154(6):1923-32. PubMed ID: 10362819
[TBL] [Abstract][Full Text] [Related]
16. Differential effects of administration of a human anti-CD4 monoclonal antibody, HM6G, in nonhuman primates.
Fishwild DM; Hudson DV; Deshpande U; Kung AH
Clin Immunol; 1999 Aug; 92(2):138-52. PubMed ID: 10444358
[TBL] [Abstract][Full Text] [Related]
17. Study on the expression of co-stimulatory marker CD134 on CD4+ T cells in HIV-1-infected individuals.
Palanee A; Pattarawat T
J Immunoassay Immunochem; 2012; 33(2):195-202. PubMed ID: 22471609
[TBL] [Abstract][Full Text] [Related]
18. PLGA-nanoparticle mediated delivery of anti-OX40 monoclonal antibody enhances anti-tumor cytotoxic T cell responses.
Chen M; Ouyang H; Zhou S; Li J; Ye Y
Cell Immunol; 2014 Feb; 287(2):91-9. PubMed ID: 24487032
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics, dosimetry, and toxicity of the targetable atomic generator, 225Ac-HuM195, in nonhuman primates.
Miederer M; McDevitt MR; Sgouros G; Kramer K; Cheung NK; Scheinberg DA
J Nucl Med; 2004 Jan; 45(1):129-37. PubMed ID: 14734685
[TBL] [Abstract][Full Text] [Related]
20. High levels of human antigen-specific CD4+ T cells in peripheral blood revealed by stimulated coexpression of CD25 and CD134 (OX40).
Zaunders JJ; Munier ML; Seddiki N; Pett S; Ip S; Bailey M; Xu Y; Brown K; Dyer WB; Kim M; de Rose R; Kent SJ; Jiang L; Breit SN; Emery S; Cunningham AL; Cooper DA; Kelleher AD
J Immunol; 2009 Aug; 183(4):2827-36. PubMed ID: 19635903
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
